NCT06338761Completed
Switching to E-cigarette After PCI
Prognostic Impact of Switching to E-Cigarette Use in Smokers With Coronary Artery Disease Following Percutaneous Coronary Intervention: A Nationwide Cohort Study
Source: ClinicalTrials.gov · Last updated 21 May 2025
Brief summary (registry, in English)
Despite the increasing popularity of electronic cigarettes (E-cigarettes), the prognostic impact of switching to E-cigarettes in smokers with coronary artery disease (CAD) who underwent percutaneous coronary intervention (PCI) remains uncertain.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 17973 (actual)
- First submitted
- 24 Mar 2024
- Start date
- 1 Jan 2024
- Primary completion date
- 31 Dec 2024
- Lead sponsor
- Samsung Medical Center
- Diseases
- Coronary artery disease
- NCT number
- NCT06338761
What you commit to
- Study type: Observational
- Participants enrolled: 17973
- From 1 Jan 2024 to the primary completion date, 31 Dec 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Newly developed acute MI or received additional PCI or CABG from the index PCI date to the study index date
Other illness
- history of cancer
- history of ischemic stroke
Other
- died within the first 3 months of follow-up from the index date
Who the study is looking for
- patients who underwent health screening 3 years before and after the PCI
Age in the registry: 20 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Samsung Medical Center Coordinator of this site? Confirm its status | Seoul | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.